Promising New Drug for Aggressive Stage IV Breast Cancer Encounters Setback

Home Blog Promising New Drug for Aggressive Stage IV Breast Cancer Encounters Setback

A new drug for stage IV breast cancer was recently delayed by the Food and Drug Administration. The drug, scaituzumab govitecan, demonstrated substantial improvement over existing therapies. This drug is able to hone in on the cancer and delivers chemotherapy right to it. The delay was due to issues on chemistry, manufacturing and control matters. No additional clinical or preclinical data needs to be generated. The drug producer will be requesting a meeting with the FDA as soon as possible with the goal to get this important drug to patients as soon as possible.

Read more about the drug and one person's story from ABC News.

0 comments

Back to Top